CA2636838C - Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect - Google Patents

Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect Download PDF

Info

Publication number
CA2636838C
CA2636838C CA2636838A CA2636838A CA2636838C CA 2636838 C CA2636838 C CA 2636838C CA 2636838 A CA2636838 A CA 2636838A CA 2636838 A CA2636838 A CA 2636838A CA 2636838 C CA2636838 C CA 2636838C
Authority
CA
Canada
Prior art keywords
alkoxy
alkyl
amino
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2636838A
Other languages
English (en)
French (fr)
Other versions
CA2636838A1 (en
Inventor
Gerard Moinet
Daniel Cravo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poxel SA
Original Assignee
Poxel SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel SA filed Critical Poxel SA
Publication of CA2636838A1 publication Critical patent/CA2636838A1/en
Application granted granted Critical
Publication of CA2636838C publication Critical patent/CA2636838C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2636838A 2006-01-13 2006-12-18 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect Expired - Fee Related CA2636838C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR06/00347 2006-01-13
FR0600347A FR2896161B1 (fr) 2006-01-13 2006-01-13 Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
PCT/EP2006/012183 WO2007079915A2 (en) 2006-01-13 2006-12-18 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect

Publications (2)

Publication Number Publication Date
CA2636838A1 CA2636838A1 (en) 2007-07-19
CA2636838C true CA2636838C (en) 2015-05-05

Family

ID=36658622

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2636838A Expired - Fee Related CA2636838C (en) 2006-01-13 2006-12-18 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect

Country Status (22)

Country Link
US (1) US8217040B2 (cg-RX-API-DMAC10.html)
EP (1) EP1971329B1 (cg-RX-API-DMAC10.html)
JP (1) JP2009523140A (cg-RX-API-DMAC10.html)
KR (1) KR101482686B1 (cg-RX-API-DMAC10.html)
CN (1) CN101355931A (cg-RX-API-DMAC10.html)
AR (1) AR059034A1 (cg-RX-API-DMAC10.html)
AU (1) AU2006334732B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0620983B8 (cg-RX-API-DMAC10.html)
CA (1) CA2636838C (cg-RX-API-DMAC10.html)
CY (1) CY1119872T1 (cg-RX-API-DMAC10.html)
DK (1) DK1971329T3 (cg-RX-API-DMAC10.html)
EA (1) EA016127B1 (cg-RX-API-DMAC10.html)
ES (1) ES2647912T3 (cg-RX-API-DMAC10.html)
FR (1) FR2896161B1 (cg-RX-API-DMAC10.html)
HU (1) HUE037217T2 (cg-RX-API-DMAC10.html)
IL (1) IL192595A (cg-RX-API-DMAC10.html)
LT (1) LT1971329T (cg-RX-API-DMAC10.html)
PL (1) PL1971329T3 (cg-RX-API-DMAC10.html)
PT (1) PT1971329T (cg-RX-API-DMAC10.html)
SI (1) SI1971329T1 (cg-RX-API-DMAC10.html)
WO (1) WO2007079915A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200806946B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
EP3691650A1 (en) 2017-10-02 2020-08-12 Poxel Methods of treating heart failure with preserved ejection fraction
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
EP4014962A1 (de) * 2020-12-16 2022-06-22 Novigo GmbH & Co. KG Zusammensetzung mit osmotisch wirksamer substanz und verwendung der zusammensetzung
FR3149774B1 (fr) * 2024-01-11 2025-06-20 Fabre Pierre Dermo Cosmetique 5,6,5’,6’-tétraphényl-3,3’-(1,4-phénylène)-bis[1,2,4]triazine pour améliorer l’aspect des cicatrices et/ou réduire les marques cicatricielles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150362A (en) * 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
CN1290264A (zh) * 1997-12-12 2001-04-04 艾博特公司 三嗪类血管生成抑制剂
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
US7622469B2 (en) * 2002-12-17 2009-11-24 Hamari Chemicals, Ltd. 2,4-diamino-1,3,5-triazine derivatives
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance

Also Published As

Publication number Publication date
KR101482686B1 (ko) 2015-01-14
PT1971329T (pt) 2017-11-24
SI1971329T1 (en) 2018-03-30
IL192595A (en) 2013-04-30
BRPI0620983A2 (pt) 2011-11-29
US8217040B2 (en) 2012-07-10
AU2006334732B2 (en) 2012-05-17
CA2636838A1 (en) 2007-07-19
EA016127B1 (ru) 2012-02-28
CY1119872T1 (el) 2018-06-27
BRPI0620983B8 (pt) 2021-05-25
LT1971329T (lt) 2018-01-25
CN101355931A (zh) 2009-01-28
FR2896161B1 (fr) 2008-04-04
EA200801678A1 (ru) 2008-12-30
WO2007079915A2 (en) 2007-07-19
HUE037217T2 (hu) 2018-08-28
DK1971329T3 (en) 2017-12-04
AR059034A1 (es) 2008-03-12
IL192595A0 (en) 2009-02-11
AU2006334732A1 (en) 2007-07-19
PL1971329T3 (pl) 2018-03-30
EP1971329A2 (en) 2008-09-24
EP1971329B1 (en) 2017-10-11
US20100168115A1 (en) 2010-07-01
KR20080088629A (ko) 2008-10-02
FR2896161A1 (fr) 2007-07-20
WO2007079915A3 (en) 2007-08-30
ZA200806946B (en) 2009-11-25
JP2009523140A (ja) 2009-06-18
ES2647912T3 (es) 2017-12-27
BRPI0620983B1 (pt) 2019-09-17

Similar Documents

Publication Publication Date Title
AU2001264011B2 (en) Use of biguanide derivatives for making a medicine having a wound healing effect
KR101932668B1 (ko) 쉬나무 추출물을 유효성분으로 하는 창상 치유용 약학 조성물
Türkyılmaz et al. Mitomycin C prevents strictures in caustic esophageal burns in rats
CN106659713A (zh) 外用组合物
JP4831849B2 (ja) 活性酸素消去剤およびその用途
EP1971329B1 (en) Triazine derivatives for use in a cicatrising treatment
JP4155430B2 (ja) 皮膚老化抑制剤およびその用途
JPWO2005025598A1 (ja) Propionibacteriumacnesに対する抗菌剤
JP7001356B2 (ja) 皮膚色素沈着抑制剤
JP5438239B1 (ja) シコニン誘導体を有するペリオスチンの発現抑制剤
HK1128406A (en) Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect
KR101833025B1 (ko) 희렴 추출물을 포함하는 여드름 개선용, 예방 및 치료용 조성물
US11773081B2 (en) Pharmaceutical composition for preventing or treating wound, comprising indirubin derivative as active ingredient
CN103520204B (zh) 一种含氯诺昔康和聚维酮碘的药物组合物
KR20250108066A (ko) 튜불린 저해제를 포함하는 병용요법을 이용한 피부 질환 예방 또는 치료용 조성물
CN121059587A (zh) 一种大蒜活性成分在制备用于预防和或辅助治疗皮肤鳞状细胞癌的药物中的应用
KR20170110977A (ko) 희렴 추출물을 포함하는 여드름 개선용, 예방 및 치료용 조성물
KR20160044214A (ko) Abh 항원의 발현을 조절하는 물질을 포함하는 모공 축소용 조성물
KR20100011465A (ko) 커큐민을 유효성분으로 포함하는 피판 치료용 조성물

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20211220